News

Despite a tremendous burden regarding migraine-related disability and expenditure, headache disorders remain underdiagnosed and undertreated, and only a small percentage of patients report satisfaction with the treatment received.

Neurology News Network for the week ending July 1, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 30, 2023.

The chief scientific officer at Liberate Bio discussed how through the advancement of nonviral delivery technologies and nucleic acid therapeutics, genetic medicines can potentially bring relief to patients with Duchenne muscular dystrophy. [WATCH TIME: 5 minutes]

A group of experts in the care of patients with neurological conditions—Amynah Pradhan, PhD; Katherine Podraza, MD, PhD; Elizabeth K. Seng, PhD; Olivia Begasse de Dhaem, MD, FAHS; Sait Ashina, MD, FAHS—shared their perspectives on hot topics of treatment and management in headache/migraine from the 2023 American Headache Society Annual Scientific Meeting.

The head of the MS Center at Methodist Hospitals and assistant professor of neurology at Indiana University talked about the significance of diversity and the health disparities faced by patients with multiple sclerosis in the LGBTQ+ community. [WATCH TIME: 3 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Amit Bar-Or, MD; Gavin Giovannoni, MBBCh, PhD; Dayna Johnson, PhD, MPH, MSW, MS; John Winkelman, MD, PhD; Laxman Bahroo, DO; Ling Wan-Albert, OTD, OTR/L; Sara Pavitt, MD; and Ali Ezzati, MD. [LISTEN TIME: 28 minutes]

Review the latest peer-reviewed articles dedicated to the multidisciplinary management of multiple sclerosis published in the International Journal of MS Care.

A group of experts in the care of patients with neurological conditions—Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath; Andrew Solomon, MD; Anne H. Cross, MD; Anthony Feinstein, MPhil, PhD, FRCP; Brian G. Weinshenker, MD, FRCP—shared their perspectives on hot topics of treatment and management in multiple sclerosis from the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting.

As a recap from AHS 2023, get caught up on some of the latest news in neurology as the NeurologyLive® team shares some of our data updates.

The pain management specialist and headache neurologist at the University of California San Diego Center for Pain Medicine discussed the different forms of cannabis and the need to conduct larger, multicenter studies to better understand its effects in migraine. [WATCH TIME: 3 minutes]

John DeLuca, PhD, senior vice president for Research and Training at Kessler Foundation, discussed the challenges in understanding and measuring fatigue in patients with multiple sclerosis.

As a recap from CMSC 2023, get caught up on some of the latest news in neurology as the NeurologyLive® team shares some of our data updates.

The undergraduate program director at the University of South Carolina provided perspective on the factors that go into building an equitable and effective medical course for young medical professionals. [WATCH TIME: 5 minutes]

As part of our monthly clinician spotlight, NeurologyLive® highlighted migraine expert Jason J. Sico, MD, MHS, national director of the Headache Centers of Excellence program within the Veterans Health Administration.

The associate professor at Johns Hopkins School of Nursing provided insight on a presentation at SLEEP 2023, and whether neurofilament light should be more considered when assessing elderly patients with sleep disorders. [WATCH TIME: 5 minutes]

The professor of anesthesiology at Washington University in St. Louis provided insight on his presentation at AHS 2023 discussing the need to engage underserved populations.

With the approval, Roche has 3 FDA-cleared tests that are reflective of the main Alzheimer disease pathologies and help clinicians more completely define the disease biologically.

The associate professor of environmental and occupational Health at the University of California, Irvine, talked about the impact of concentrated particulate matter or air pollution on cognitive function in animal models. [WATCH TIME: 5 minutes]

Marisa Whalen, PharmD, associate director of Medical Affairs at Jazz Pharmaceuticals, discussed presentations at SLEEP 2023 on the real-world burdens of idiopathic hypersomnia and the smooth transition to low sodium oxybate in patients with narcolepsy.

In a phase 3 study, rozanolixizumab demonstrated statistically significant differences vs placebo on primary and secondary outcomes over a 43-day treatment period.

At 6 months, a larger proportion of patients on standard of care experienced unfavorable outcomes, as demonstrated by modified Rankin Scale scores greater than 3, in comparison with lumbar drainage.

In addition to increased relapse rates, use of fingolimod was associated with a 49% higher risk for disability accumulation in comparison with ocrelizumab.

At ATMRD 2023, Lori DePorter, global ambassador for the PMD alliance, talked from the patient experience about the need for improved communication between care teams and support groups in Parkinson disease. [WATCH TIME: 3 minutes]

Episode 35 of the AUPN Leadership Minute features Tracey A. Milligan, MD, of New York Medical College; and Carl Gold, MD, MS, of Stanford University. [WATCH TIME: 5 minutes]

Following the positive results, uniQure expects to initiate a third cohort in the ongoing trial to further investigate both low and high doses of AMT-130 in combination with perioperative immunosuppression.

The sleep epidemiologist and assistant professor at the Rollins School of Public Health at Emory University discussed the multi-level effort needed to improve sleep issues seen in individuals most impacted by social determinants of health. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.